Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gastrointestinal tumors
Biotech
Gilead stops phase 3 TIGIT trial, doubles down on other studies
Arcus and Gilead are rethinking their TIGIT strategy, stopping a phase 3 lung cancer TIGIT clinical trial and walking away from another project.
Nick Paul Taylor
Jan 30, 2024 8:09am
Gilead-Arcus' TIGIT gets high response in gastric cancer
Nov 7, 2023 9:40am
Alimentiv, Summit Clinical partner to improve research on NASH
Nov 10, 2022 5:03am
IDRx nabs $122M to address precision medicine 'whack-a-mole'
Aug 2, 2022 6:30am
AstraZeneca bets $25M on pre-clinic bispecific versus hot target
Apr 7, 2022 7:00am
Carl June's latest CAR-T work taps llamas for GI cancers
Mar 29, 2022 9:00am